These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 37169105)

  • 1. Corrigendum to "Non-covalent strategies to functionalize polymeric nanoparticles with NGR peptides for targeting breast cancer" [Int. J. Pharm. 633 (2023) 122618].
    Conte C; Longobardi G; Barbieri A; Palma G; Luciano A; Dal Poggetto G; Avitabile C; Pecoraro A; Russo A; Russo G; Laurienzo P; Romanelli A; Quaglia F
    Int J Pharm; 2023 Jun; 641():123045. PubMed ID: 37169105
    [No Abstract]   [Full Text] [Related]  

  • 2. Non-covalent strategies to functionalize polymeric nanoparticles with NGR peptides for targeting breast cancer.
    Conte C; Longobardi G; Barbieri A; Palma G; Luciano A; Dal Poggetto G; Avitabile C; Pecoraro A; Russo A; Russo G; Laurienzo P; Romanelli A; Quaglia F
    Int J Pharm; 2023 Feb; 633():122618. PubMed ID: 36657553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Corrigendum to "Manufacturing drug co-loaded liposomal formulations targeting breast cancer: Influence of preparative method on liposomes characteristics and in vitro toxicity" [Int. J. Pharm. 590 (2020) 119926].
    Gkionis L; Campbell RA; Aojula H; Harris LK; Tirella A
    Int J Pharm; 2021 Apr; 599():120440. PubMed ID: 33726932
    [No Abstract]   [Full Text] [Related]  

  • 4. Corrigendum to "SN38 conjugated hyaluronic acid gold nanoparticles as a novel system against metastatic colon cancer cells" [Int. J. Pharm. 526(1-2) (2017) 339-352].
    Hosseinzadeh H; Atyabi F; Varnamkhasti BS; Hosseinzadeh R; Ostad SN; Ghahremani MH; Dinarvand R
    Int J Pharm; 2022 Oct; 626():122145. PubMed ID: 36058773
    [No Abstract]   [Full Text] [Related]  

  • 5. Corrigendum to "Inhaled nanoparticles-An updated review" [Int. J. Pharm. 587 (2020) 119671].
    Praphawatvet T; Peters JI; Williams RO
    Int J Pharm; 2020 Oct; 588():119873. PubMed ID: 32950278
    [No Abstract]   [Full Text] [Related]  

  • 6. Corrigendum to "Hepatotoxicity evaluation of dextran stabilized iron oxide nanoparticles in Wistar rats" [Int. J. Pharm. 509(1-2) (2016) 28-34].
    Easo SL; Mohanan PV
    Int J Pharm; 2021 Sep; 607():121028. PubMed ID: 34452792
    [No Abstract]   [Full Text] [Related]  

  • 7. Corrigendum to "Toxicity, toxicokinetics and biodistribution of dextran stabilized Iron oxide Nanoparticles for biomedical applications" [Int. J. Pharm. 511 (2016) 586-598].
    Remya NS; Syama S; Sabareeswaran A; Mohanan PV
    Int J Pharm; 2021 Sep; 606():120930. PubMed ID: 34332819
    [No Abstract]   [Full Text] [Related]  

  • 8. Corrigendum to "Nrp-1 receptor targeting peptide-functionalized TPGS micellar nanosystems to deliver 10-hydroxycampothecin for enhanced cancer chemotherapy" [Int. J. Pharm. 547(1-2) (2018) 582-592].
    Mozhi A; Ahmad I; Kaleem QM; Tuguntaev RG; Eltahan AS; Wang C; Yang R; Li C; Liang XJ
    Int J Pharm; 2022 Nov; 627():122237. PubMed ID: 36182626
    [No Abstract]   [Full Text] [Related]  

  • 9. Corrigendum to "Characterization of nanoparticles made of ethyl cellulose and stabilizing lipids: Mode of manufacturing, size modulation, and study of their effect on keratinocytes" [Int. J. Pharm. 607 (2021) 121003].
    Zamansky M; Zehavi N; Ben-Shabat S; Sintov AC
    Int J Pharm; 2021 Nov; 609():121177. PubMed ID: 34656377
    [No Abstract]   [Full Text] [Related]  

  • 10. Corrigendum to "Molecular insights and novel approaches for targeting tumor metastasis" [Int. J. Pharm. 585 (2020) 119556].
    Das SS; Alkahtani S; Bharadwaj P; Ansari MT; ALKahtani MDF; Pang Z; Hasnain MS; Nayak AK; Aminabhavi TM
    Int J Pharm; 2020 Nov; 590():119967. PubMed ID: 33071034
    [No Abstract]   [Full Text] [Related]  

  • 11. Corrigendum to "The enhancement of gene silencing efficiency with chitosan-coated liposome formulations of siRNAs targeting HIF-1α and VEGF" [Int. J. Pharm. 478 (2015) 147-154].
    Şalva E; Turan SÖ; Eren F; Akbuğa J
    Int J Pharm; 2017 Mar; 520(1-2):297. PubMed ID: 28209238
    [No Abstract]   [Full Text] [Related]  

  • 12. Corrigendum to "Apoferritin nanocages loading mertansine enable effective eradiation of cancer stem-like cells in vitro" [Int. J. Pharm. 553 (2018) 201-209].
    Tan T; Wang Y; Wang H; Cao H; Wang Z; Wang J; Li J; Li Y; Zhang Z; Wang S
    Int J Pharm; 2020 Feb; 576():119054. PubMed ID: 31982211
    [No Abstract]   [Full Text] [Related]  

  • 13. Corrigendum to 'A surfactant-like chemotherapeutic agent as a nanocarrier for delivering photosensitizers against cancer: A facile drug-delivering-drug strategy' [Int. J. Pharm. 562 (2019) 313-320].
    Wang Z; Sun M; Liu T; Tan X; Zhang H; Zhang X; He Z; Sun J
    Int J Pharm; 2019 Aug; 567():118463. PubMed ID: 31256941
    [No Abstract]   [Full Text] [Related]  

  • 14. Comparison of methods for predicting dissolution and the theoretical implications of particle-size-dependent solubility.
    Johnson KC
    J Pharm Sci; 2012 Feb; 101(2):681-9. PubMed ID: 21989679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Corrigendum to "Paclitaxel-loaded polymeric nanoparticles combined with chronomodulated chemotherapy on lung cancer: In vitro and in vivo evaluation" [Int. J. Pharmaceut. 516 (2017) 313-322].
    Hu J; Fu S; Peng Q; Han Y; Xie J; Zan N; Chen Y; Fan J
    Int J Pharm; 2020 Jan; 573():118878. PubMed ID: 31784050
    [No Abstract]   [Full Text] [Related]  

  • 16. Corrigendum to "Development of intranasal implantable devices for schizophrenia treatment" [Int. J. Pharm. 624 (2021) 122061].
    Utomo E; Domínguez-Robles J; Moreno-Castellanos N; Stewart SA; Picco CJ; Anjani QK; Simón JA; Peñuelas I; Donnelly RF; Larrañeta E
    Int J Pharm; 2023 Jan; 630():122475. PubMed ID: 36517342
    [No Abstract]   [Full Text] [Related]  

  • 17. Corrigendum to "Nanocarrier-based dermopharmaceutical formulations for the topical management of atopic dermatitis" [Int. J. Pharm. 618 (2022) 121656].
    Paiva-Santos AC; Gama M; Peixoto D; Sousa-Oliveira I; Ferreira-Faria I; Zeinali M; Abbaspour-Ravasjani S; Mascarenhas-Melo F; Hamishehkar H; Veiga F
    Int J Pharm; 2022 Nov; 627():122146. PubMed ID: 36167592
    [No Abstract]   [Full Text] [Related]  

  • 18. Corrigendum to "Powder cohesion and energy to break an avalanche: Can we address surface heterogeneity?" [Int. J. Pharm. 626 (2022) 122198].
    Brokešová J; Niederquell A; Kuentz M; Zámostný P; Vraníková B; Šklubalová Z
    Int J Pharm; 2023 Jan; 631():122485. PubMed ID: 36529577
    [No Abstract]   [Full Text] [Related]  

  • 19. Corrigendum to "Topical delivery of aqueous micellar Resolvin E1 analog (RX-10045)" [Int. J. Pharm. 498 (2016) 326-334].
    Cholkar K; Gilger BC; Mitra AK
    Int J Pharm; 2016 Jul; 509(1-2):528. PubMed ID: 27350413
    [No Abstract]   [Full Text] [Related]  

  • 20. Corrigendum to "Transdermal delivery of vancomycin hydrochloride: Influence of chemical and physical permeation enhancers" [Int. J. Pharm. 602 (2021) 120663].
    Datta D; Panchal DS; Venuganti VVK
    Int J Pharm; 2021 Nov; 609():121171. PubMed ID: 34635371
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.